April 4, 2018

The Honorable Roy Blunt
Chairman
Senate Appropriations Committee
Subcommittee on LHHS
United States Senate
Washington, DC 20510

The Honorable Patty Murray
Ranking Member
Senate Appropriations Committee
Subcommittee on LHHS
United States Senate
Washington, DC 20510

The Honorable Tom Cole
Chairman
House Appropriations Committee
Subcommittee on LHHS
U.S. House of Representatives
Washington, DC 20515

The Honorable Rosa DeLauro
Ranking Member
House Appropriations Committee
Subcommittee on LHHS
U.S. House of Representatives
Washington, DC 20515

Dear Chairman Blunt, Chairman Cole, Ranking Member Murray and Ranking Member DeLauro:

On behalf of the Diabetes Advocacy Alliance (DAA), we are writing to express our sincere appreciation for the $25.3 million in funding provided to the National Diabetes Prevention Program (National DPP) at the Centers for Disease Control and Prevention (CDC) in the fiscal year 2018 omnibus bill.

The DAA is a coalition of 24 diverse member organizations, representing patient, professional and trade associations, other non-profit organizations, and corporations, all united in the desire to change the way diabetes is viewed and treated in America. Since 2010, the DAA has worked to increase awareness of, and action on, the diabetes epidemic among legislators and policymakers. The organizations that comprise the DAA share a common goal of elevating diabetes on the national agenda so we may ultimately defeat diabetes.

As you know, over 30 million Americans have diabetes and an additional 84 million adults are at risk of developing the disease. By 2050, it is estimated that one out of every three Americans will have diabetes. In addition, the annual cost of diagnosed diabetes has skyrocketed to $327 billion in 2017, an increase of 26 percent in just five years. The cost of diabetes will continue to rise unless something is done. Both the human and economic tolls of this disease are devastating.

While diabetes poses serious problems for our families, employers, insurers, and government, the National DPP has the potential to change the trajectory of this disease. We commend you for your recognition of the valuable work of the National DPP to reduce the growing problem of prediabetes and type 2 diabetes in the United States. We look forward to continuing to work with you to support this valuable, evidence-based program.

Sincerely,

Meredith Dyer
DAA Co-chair
Endocrine Society

Karin Gillespie
DAA Co-chair
Novo Nordisk, Inc.

Meghan Riley
DAA Co-chair
American Diabetes Association

www.diabetesadvocacyalliance.org